Paul Hastings LLP advised Masimo LHC Limited on the deal.
Masimo LHC Limited, a wholly-owned indirect subsidiary of Masimo Corporation announced its recommended cash acquisition of the entire issued and to be issued share capital of LidCo Group plc.
Masimo is a global medical technology company that develops, manufactures, distributes, and licenses innovative patient monitoring technologies, medical devices, and a wide array of sensors. LidCo is a market leader for the provision of advanced hemodynamic monitoring products in the UK and has a growing presence in the US and many other international markets.
LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO’s products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.
The Paul Hastings team was led by London partner Matthew Poxon (Picture) and senior associate David Prowse with support from corporate associates Catherine Kennedy and Rebecca Denton. The Paul Hastings team also included employment partner Suzanne Horne and associate Aashna Parekh and tax partner Jiten Tank and associate Hannah Gray. Masimo relationship partner Jeff Hartlin and associate Regina Mendoza advised on the US securities aspects of the transaction.
Involved fees earner: Hannah Gray – Paul Hastings; Jeff Hartlin – Paul Hastings; Suzanne Horne – Paul Hastings; Catherine Kennedy – Paul Hastings; Aashna Parekh – Paul Hastings; Matthew Poxon – Paul Hastings; David Prowse – Paul Hastings; Jiten Tank – Paul Hastings;
Law Firms: Paul Hastings;
Clients: Masimo LHC Limited;